| pubmed-article:1472922 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1472922 | lifeskim:mentions | umls-concept:C0024299 | lld:lifeskim |
| pubmed-article:1472922 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:1472922 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
| pubmed-article:1472922 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:1472922 | lifeskim:mentions | umls-concept:C0441889 | lld:lifeskim |
| pubmed-article:1472922 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:1472922 | pubmed:dateCreated | 1993-2-2 | lld:pubmed |
| pubmed-article:1472922 | pubmed:abstractText | We have suggested a growth stimulatory role of lymphoma cells in culture by interleukin 6. To test the hypothesis that IL-6 may have a role in vivo, the plasma of lymphoma patients was assayed for the presence of IL-6 bioactivity. A significantly greater proportion of lymphoma patients had elevated IL-6 levels (23 of 40) compared to controls (3 of 35). In follow-up, eight of 15 patients with previously elevated levels returned with decreased or undetectable levels of IL-6 post radio- or chemotherapy. This response was seen primarily in those with intermediate or high grade lymphomas. In contrast no change in IL-6 levels was seen in patients with low grade lymphoma despite measurable reductions in tumor size in both groups. | lld:pubmed |
| pubmed-article:1472922 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1472922 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1472922 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1472922 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1472922 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1472922 | pubmed:month | May | lld:pubmed |
| pubmed-article:1472922 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:1472922 | pubmed:author | pubmed-author:YeeCC | lld:pubmed |
| pubmed-article:1472922 | pubmed:author | pubmed-author:MindenM DMD | lld:pubmed |
| pubmed-article:1472922 | pubmed:author | pubmed-author:MessnerH AHA | lld:pubmed |
| pubmed-article:1472922 | pubmed:author | pubmed-author:SutcliffeSS | lld:pubmed |
| pubmed-article:1472922 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1472922 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:1472922 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1472922 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1472922 | pubmed:pagination | 123-9 | lld:pubmed |
| pubmed-article:1472922 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:meshHeading | pubmed-meshheading:1472922-... | lld:pubmed |
| pubmed-article:1472922 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1472922 | pubmed:articleTitle | Interleukin-6 levels in the plasma of patients with lymphoma. | lld:pubmed |
| pubmed-article:1472922 | pubmed:affiliation | Department of Medicine and Bioresearch, Ontario Cancer Institute, Toronto, Canada. | lld:pubmed |
| pubmed-article:1472922 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1472922 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
